Glimepirida Cinfa (Glimepiride)

Glimepirida Cinfa is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus when diet, exercise, and lifestyle measures alone are insufficient.

• As monotherapy in patients whose glycemic control is not achieved with non‑pharmacologic measures.
• In combination with metformin when additional glucose lowering is required.
• As part of a fixed‑dose combination regimen with other oral antidiabetics, if approved.
• For patients who can tolerate sulfonylureas and have preserved pancreatic β‑cell function.
• To achieve target HbA1c levels as part of an individualized treatment plan.

The safety profile of Glimepirida Cinfa includes a range of adverse effects that are classified by frequency and clinical significance.

Common

• Mild hypoglycemia, especially if meals are skipped or delayed.
• Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia.
• Headache or dizziness.
• Weight gain due to increased insulin activity.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness).
• Allergic reactions including rash, pruritus, or angio‑edema.
• Hematologic abnormalities such as leukopenia or thrombocytopenia.

Before prescribing Glimepirida Cinfa, clinicians should evaluate several patient‑specific factors and monitor for potential risks during therapy.

• Assess renal and hepatic function; dose adjustment may be needed in impairment.
• Verify that the patient has adequate pancreatic β‑cell reserve.
• Caution in elderly patients due to increased susceptibility to hypoglycemia.
• Avoid use during pregnancy and lactation unless benefits outweigh risks.
• Review concomitant use of other hypoglycemic agents to prevent additive effects.
• Monitor for signs of cardiovascular disease, as sulfonylureas may affect cardiac ischemic preconditioning.
• Educate patients on recognizing and managing hypoglycemia.

Glimepirida Cinfa can interact with several medications, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid

• Concurrent use with other sulfonylureas or insulin, which may cause profound hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that increase glimepiride plasma concentrations.
• MAO‑B inhibitors (e.g., selegiline) that may potentiate hypoglycemic effects.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Thiazide diuretics, which may raise blood glucose levels.
• Corticosteroids or atypical antipsychotics that can reduce glimepiride efficacy.
• NSAIDs, especially high‑dose ibuprofen, that may affect renal function and drug clearance.